CD19嵌合抗原受体T细胞构建体系的优化及体内外杀伤效果观察
该研究优化小鼠CD3+ T细胞体外活化体系与逆转录病毒感染时间,成功构建小鼠CD19 CAR-T细胞;该细胞体外可特异性杀伤A20淋巴瘤细胞,体内第12天显著清除脾脏和骨髓CD19+细胞,脾脏(0.36±0.04)%对(47.00±13.46)%,P<0.001。
要点
- 包被抗CD3/CD28抗体活化CD3+ T细胞效果最佳,刺激后24~48 h细胞活性良好。
- 逆转录病毒感染CD3+ T细胞效率为(32.27±7.56)%,mCD19 CAR-T构建稳定。
- mCD19 CAR-T在体内外均具杀伤能力,第12天脾脏和骨髓CD19+细胞清除显著。
核心结论
- 获得优化的CD3+ T细胞活化刺激体系和最佳感染时间,稳定构建了抗mCD19 CAR-T细胞,并在体内外验证其具备良好的杀伤能力。
研究设计与样本
- 研究为实验研究,采用磁珠分选纯化小鼠脾脏CD3+ T细胞,比较3种刺激活化条件并检测8、24、48和72 h细胞活性。
- 用含小鼠CD19抗体scFv质粒转染Plat-E细胞包装逆转录病毒,感染活化的CD3+ T细胞制备mCD19 CAR-T。
- mCD19 CAR-T与B淋巴瘤细胞株A20体外共培养检测杀伤,并输注淋巴瘤小鼠模型检测体内杀伤与分布。
主要发现
- 包被抗CD3/CD28抗体刺激活化效果最佳,刺激后24~48 h细胞活性较好。
- 抗mCD19逆转录病毒感染CD3+ T细胞效率为(32.27±7.56)%。
- mCD19 CAR-T可特异性杀伤A20细胞,48 h时A20细胞凋亡率为24.3%。
- 输注mCD19 CAR-T第6天脾脏CD19+细胞比例为(1.83±0.58)%,原文结论称显著降低。
- 第12天脾脏CD19+细胞为(0.36±0.04)%对A20组(47.00±13.46)%,P<0.001;骨髓为(1.82±0.29)%对(37.30±1.44)%,P<0.0001。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To optimize the stimulation and activation system of mouse CD3(+) T cells in vitro and explore the optimal infection time of CD3(+) T cells to establish mouse CD19 chimeric antigen receptor T cells (mCD19 CAR-T) , and to also verify its killing effect in vivo and in vitro. Method: Splenic CD3(+)T cells were isolated and purified using magnetic beads, and the cells were cultured in Soluble anti-CD3/CD28, PMA+Ionomycin, and Plated anti-CD3/CD28. Cell activation and apoptosis were assessed by flow cytometry after 8, 24, 48, and 72 hours. ScFv plasmid of mouse CD19 antibody was transfected to plat-E cells to package retrovirus. Activated CD3(+) T cells were infected to construct mouse-specific CD19 chimeric antigen receptor T cells (mCD19 CAR-T) , and mCD19 CAR-T cells were co-cultured with B-cell lymphoma cell line A20 in vitro. The specific toxicity of A20 was detected by flow cytometry, and mCD19 CAR-T cells were infused into the lymphoma mouse model to detect its killing effect and distribution. Results: The activation effect of Plated anti-CD3/CD28 on CD3(+) T cells was superior, with the cells exhibiting good viability 24-48 hours after stimulation. Established mCD19 CAR-T cells with stable efficiency[ (32.27±7.56) % ] were specifically able to kill A20 tumor cells (The apoptosis rate was 24.3% at 48 h) . In vivo detection showed a non-significant decrease in the percentage[ (1.83±0.58) % ] of splenic CD19(+) cells 6 days after mCD19 CAR-T cell infusion. A marked clearance in bone marrow and spleen appeared on day 12 compared with the A20 group, and this difference was statistically significant[spleen: (0.36±0.04) % vs (47.00±13.46) % , P<0.001; bone marrow: (1.82±0.29) % vs (37.30±1.44) % , P<0.0001]. Moreover, mCD19 CAR-T cells were distributed in high proportions in the peripheral blood, spleen, and bone marrow[ (2.90±1.12) % , (4.96±0.80) % , (13.55±1.56) % ]. Conclusion: This study demonstrated an optimized activation system and the optimal infection time of CD3(+) T cells. Furthermore, stable constructed mCD19 CAR-T cells showed a remarkable killing ability in vitro and in vivo. 目的: 优化小鼠CD3(+)T细胞体外刺激活化体系及最佳感染时间,构建小鼠CD19嵌合抗原受体T细胞(mCD19 CAR-T),并验证其在体内外的杀伤效果。 方法: 磁珠分选纯化小鼠的脾脏CD3(+)T细胞,在可溶性抗CD3/CD28抗体、佛波酯+离子霉素、包被抗CD3/CD28抗体3种不同条件下刺激培养,分别于8、24、48和72 h流式细胞术检测细胞活性情况;用包含小鼠CD19抗体的scFv质粒转染Plat-E细胞,包装逆转录病毒后感染活化的CD3(+)T细胞,制备鼠特异性的CD19嵌合抗原受体T细胞(mCD19 CAR-T)。mCD19 CAR-T细胞在体外与B淋巴瘤细胞株A20细胞共培养,利用流式细胞术检测其对A20细胞的靶向杀伤效果;建立淋巴瘤小鼠模型,体内输注mCD19 CAR-T细胞,检测CAR-T细胞的体内杀伤和分布情况。 结果: 包被抗CD3/CD28抗体的刺激活化效果最佳,且在刺激后24~48 h具有较好的细胞活性;抗mCD19的逆转录病毒感染CD3(+) T细胞效率[(32.27±7.56)%]稳定,制备的mCD19 CAR-T细胞可特异性杀伤A20肿瘤细胞,48 h时A20细胞凋亡率为24.3%;体内检测发现输注mCD19 CAR-T细胞第6天即可检测到脾脏中CD19(+)细胞比例[(1.83±0.58)%]显著降低,到建模后第12天骨髓和脾脏中CD19(+)细胞清除更为显著,与A20细胞组相比差异具有统计学意义[脾脏:(0.36±0.04)%对(47.00±13.46)%,P<0.001;骨髓:(1.82±0.29)%对(37.30±1.44)%,P<0.0001]。且mCD19 CAR-T细胞在外周血、脾脏和骨髓中均有分布,GFP(+)CD3(+) CAR-T细胞比例分别为(2.90±1.12)%、(4.96±0.80)%、(13.55±1.56)%,以骨髓中占比最高。 结论: 获得优化的CD3(+) T细胞活化刺激体系和最佳感染时间,稳定构建了抗mCD19 CAR-T细胞,并在体内外验证其具备良好的杀伤能力。.
引用
- Ren CX, Chen XX, Zhao L, et al. [Optimization of CD19 chimeric antigen receptor T cell establishment and observation of the killing effect in vitro and in vivo]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35968595. doi:10.3760/cma.j.issn.0253-2727.2022.06.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。